{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:43:35Z","timestamp":1792413815001,"version":"4.4.0"},"reference-count":280,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41571-026-01190-7","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:40:58Z","timestamp":1787154058000},"page":"849-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the landscape of targetable alterations in patients with glioblastoma"],"prefix":"10.1038","volume":"23","author":[{"given":"Elisa","family":"Aquilanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Touat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-9529","authenticated-orcid":false,"given":"Pim","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0683-4634","authenticated-orcid":false,"given":"Antonio","family":"Iavarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-497X","authenticated-orcid":false,"given":"David","family":"Capper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaquat","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-0436","authenticated-orcid":false,"given":"Roel","family":"Verhaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5127","authenticated-orcid":false,"given":"Martin","family":"van den Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-7700","authenticated-orcid":false,"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"1190_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","volume":"27","author":"M Price","year":"2025","unstructured":"Price, M. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018\u20132022. Neuro-Oncology 27, iv1\u2013iv66 (2025).","journal-title":"Neuro-Oncology"},{"key":"1190_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"1190_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","volume":"576","author":"FP Barthel","year":"2019","unstructured":"Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112\u2013120 (2019).","journal-title":"Nature"},{"key":"1190_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf177","author":"PY Wen","year":"2025","unstructured":"Wen, P. Y. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology https:\/\/doi.org\/10.1093\/neuonc\/noaf177 (2025).","journal-title":"Neuro-Oncology"},{"key":"1190_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med. 389, 589\u2013601 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR6","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet, E. et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N. Engl. J. Med. 389, 1108\u20131120 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn, L. B. et al. The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat. Med. 30, 207\u2013217 (2024).","journal-title":"Nat. Med."},{"key":"1190_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/neuonc\/noae051","volume":"26","author":"I Arrillaga-Romany","year":"2024","unstructured":"Arrillaga-Romany, I. & Miller, J. J. Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight. Neuro-Oncology 26, 991\u2013992 (2024).","journal-title":"Neuro-Oncology"},{"key":"1190_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/neuonc\/noac226","volume":"25","author":"JR McFaline-Figueroa","year":"2023","unstructured":"McFaline-Figueroa, J. R. & Wen, P. Y. Negative trials over and over again: how can we do better? Neuro-Oncology 25, 1\u20133 (2023).","journal-title":"Neuro-Oncology"},{"key":"1190_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen, P. Y. et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 23, 53\u201364 (2022).","journal-title":"Lancet Oncol."},{"key":"1190_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/neuonc\/noad008","volume":"25","author":"D Capper","year":"2023","unstructured":"Capper, D. et al. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology 25, 813\u2013826 (2023).","journal-title":"Neuro-Oncology"},{"key":"1190_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/neuonc\/noae213","volume":"27","author":"MJ van den Bent","year":"2025","unstructured":"van den Bent, M. J. et al. Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1. Neuro-Oncology 27, 331\u2013337 (2025).","journal-title":"Neuro-Oncology"},{"key":"1190_CR13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 (2018).","journal-title":"Ann. Oncol."},{"key":"1190_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117\u20131134 (2010).","journal-title":"Cell"},{"key":"1190_CR15","first-page":"430","volume":"17","author":"DA Reardon","year":"2015","unstructured":"Reardon, D. A. et al. Phase I\/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncology 17, 430\u2013439 (2015).","journal-title":"Neuro-Oncology"},{"key":"1190_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman, A. B. et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro-Oncology 25, 339\u2013350 (2023).","journal-title":"Neuro-Oncology"},{"key":"1190_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","volume":"20","author":"M Snuderl","year":"2011","unstructured":"Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810\u2013817 (2011).","journal-title":"Cancer Cell"},{"key":"1190_CR18","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1158\/2159-8290.CD-13-0879","volume":"4","author":"JM Francis","year":"2014","unstructured":"Francis, J. M. et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 4, 956\u2013971 (2014).","journal-title":"Cancer Discov."},{"key":"1190_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ccell.2019.02.007","volume":"35","author":"V Korber","year":"2019","unstructured":"Korber, V. et al. Evolutionary trajectories of IDH(WT) glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell 35, 692\u2013704.e12 (2019).","journal-title":"Cancer Cell"},{"key":"1190_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/science.1241328","volume":"343","author":"DA Nathanson","year":"2014","unstructured":"Nathanson, D. A. et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343, 72\u201376 (2014).","journal-title":"Science"},{"key":"1190_CR21","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/2159-8290.CD-24-1555","volume":"15","author":"I Noorani","year":"2025","unstructured":"Noorani, I. et al. Extrachromosomal DNA-driven oncogene spatial heterogeneity and evolution in glioblastoma. Cancer Discov. 15, 2078\u20132095 (2025).","journal-title":"Cancer Discov."},{"key":"1190_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41588-018-0105-0","volume":"50","author":"AC deCarvalho","year":"2018","unstructured":"deCarvalho, A. C. et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat. Genet. 50, 708\u2013717 (2018).","journal-title":"Nat. Genet."},{"key":"1190_CR23","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N. Engl. J. Med. 390, 1290\u20131298 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR24","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"1190_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.6004\/jnccn.2011.0038","volume":"9","author":"DA Reardon","year":"2011","unstructured":"Reardon, D. A. et al. A review of VEGF\/VEGFR-targeted therapeutics for recurrent glioblastoma. J. Natl Compr. Canc Netw. 9, 414\u2013427 (2011).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"1190_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/00000478-199807000-00004","volume":"22","author":"AS Chan","year":"1998","unstructured":"Chan, A. S. et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am. J. Surg. Pathol. 22, 816\u2013826 (1998).","journal-title":"Am. J. Surg. Pathol."},{"key":"1190_CR27","first-page":"5879","volume":"60","author":"A Maity","year":"2000","unstructured":"Maity, A., Pore, N., Lee, J., Solomon, D. & O\u2019Rourke, D. M. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3\u2019-kinase and distinct from that induced by hypoxia. Cancer Res. 60, 5879\u20135886 (2000).","journal-title":"Cancer Res."},{"key":"1190_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/1535-7163.737.3.6","volume":"3","author":"MD Hjelmeland","year":"2004","unstructured":"Hjelmeland, M. D. et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 3, 737\u2013745 (2004).","journal-title":"Mol. Cancer Ther."},{"key":"1190_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11060-015-1889-8","volume":"125","author":"MO Yu","year":"2015","unstructured":"Yu, M. O. et al. Reactive oxygen species production has a critical role in hypoxia-induced Stat3 activation and angiogenesis in human glioblastoma. J. Neurooncol. 125, 55\u201363 (2015).","journal-title":"J. Neurooncol."},{"key":"1190_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740\u2013745 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR31","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1200\/JCO.22.02772","volume":"41","author":"HS Friedman","year":"2023","unstructured":"Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 41, 4945\u20134952 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699\u2013708 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709\u2013722 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR34","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick, W. et al. Lomustine and bevacizumab in progressive glioblastoma. N. Engl. J. Med. 377, 1954\u20131963 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","volume":"20","author":"G Lombardi","year":"2019","unstructured":"Lombardi, G. et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 20, 110\u2013119 (2019).","journal-title":"Lancet Oncol."},{"key":"1190_CR36","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1200\/JCO-25-01137","volume":"44","author":"PY Wen","year":"2026","unstructured":"Wen, P. Y. et al. Evaluation of regorafenib in newly diagnosed and recurrent glioblastoma: GBM AGILE phase II\/III Bayesian randomized platform trial. J. Clin. Oncol. 44, 1676\u20131686 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.ccell.2022.08.014","volume":"40","author":"A Chryplewicz","year":"2022","unstructured":"Chryplewicz, A. et al. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. Cancer Cell 40, 1111\u20131127 e1119 (2022).","journal-title":"Cancer Cell"},{"key":"1190_CR38","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1158\/1078-0432.CCR-23-0388","volume":"29","author":"Q Xu","year":"2023","unstructured":"Xu, Q. et al. Safety and efficacy of anlotinib hydrochloride plus temozolomide in patients with recurrent glioblastoma. Clin. Cancer Res. 29, 3859\u20133866 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner, N. & Grose, R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10, 116\u2013129 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"1190_CR40","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1126\/science.1220834","volume":"337","author":"D Singh","year":"2012","unstructured":"Singh, D. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231\u20131235 (2012).","journal-title":"Science"},{"key":"1190_CR41","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","volume":"21","author":"AL Di Stefano","year":"2015","unstructured":"Di Stefano, A. L. et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin. Cancer Res. 21, 3307\u20133317 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR42","first-page":"475","volume":"19","author":"A Lasorella","year":"2017","unstructured":"Lasorella, A., Sanson, M. & Iavarone, A. FGFR-TACC gene fusions in human glioma. Neuro-Oncology 19, 475\u2013483 (2017).","journal-title":"Neuro-Oncology"},{"key":"1190_CR43","first-page":"855","volume":"123","author":"BC Parker","year":"2013","unstructured":"Parker, B. C. et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Invest. 123, 855\u2013865 (2013).","journal-title":"J. Clin. Invest."},{"key":"1190_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40478-021-01170-1","volume":"9","author":"MM Georgescu","year":"2021","unstructured":"Georgescu, M. M., Islam, M. Z., Li, Y., Traylor, J. & Nanda, A. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs. Acta Neuropathol. Commun. 9, 69 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1190_CR45","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant, S. et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 24, 925\u2013935 (2023).","journal-title":"Lancet Oncol."},{"key":"1190_CR46","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","volume":"30","author":"J Rodon","year":"2024","unstructured":"Rodon, J. et al. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat. Med. 30, 1645\u20131654 (2024).","journal-title":"Nat. Med."},{"key":"1190_CR47","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","volume":"28","author":"AB Lassman","year":"2022","unstructured":"Lassman, A. B. et al. Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study. Clin. Cancer Res. 28, 2270\u20132277 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR48","volume":"6","author":"A Picca","year":"2024","unstructured":"Picca, A. et al. TARGET: a phase I\/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed\/refractory FGFR fusion-positive glioma. Neurooncol. Adv. 6, vdae068 (2024).","journal-title":"Neurooncol. Adv."},{"key":"1190_CR49","volume":"6","author":"YT Liu","year":"2024","unstructured":"Liu, Y. T., Chen, Y. H., Chang, C. H. & Liang, H. T. Recurrent fibroblast growth factor receptor3 fusion glioblastoma treated with pemigatinib: a case report and review of the literature. Neurooncol. Adv. 6, vdae072 (2024).","journal-title":"Neurooncol. Adv."},{"key":"1190_CR50","doi-asserted-by":"publisher","unstructured":"Franceschi, E. et al. A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: results from FIGHT-209. J. Clin. Oncol. 43, https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2003 (2003).","DOI":"10.1200\/JCO.2025.43.16_suppl.2003"},{"key":"1190_CR51","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","volume":"33","author":"J Tabernero","year":"2015","unstructured":"Tabernero, J. et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 33, 3401\u20133408 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR52","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00407","volume":"8","author":"J Gong","year":"2024","unstructured":"Gong, J. et al. Phase II study of erdafitinib in patients with tumors with fibroblast growth factor receptor mutations or fusions: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol K2. JCO Precis. Oncol. 8, e2300407 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1190_CR53","first-page":"00183","volume":"2018","author":"R Okamura","year":"2018","unstructured":"Okamura, R. et al. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis. Oncol. 2018, 00183 (2018).","journal-title":"JCO Precis. Oncol."},{"key":"1190_CR54","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm.4204","volume":"22","author":"International Cancer Genome Consortium PedBrain Tumor Project.","year":"2016","unstructured":"International Cancer Genome Consortium PedBrain Tumor Project.Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat. Med. 22, 1314\u20131320 (2016).","journal-title":"Nat. Med."},{"key":"1190_CR55","first-page":"14932","volume":"8","author":"Y Kwak","year":"2015","unstructured":"Kwak, Y. et al. C-MET overexpression and amplification in gliomas. Int. J. Clin. Exp. Pathol. 8, 14932\u201314938 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"1190_CR56","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2018.09.038","volume":"175","author":"H Hu","year":"2018","unstructured":"Hu, H. et al. Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell 175, 1665\u20131678.e18 (2018).","journal-title":"Cell"},{"key":"1190_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12187-5","volume":"10","author":"AS Guerreiro Stucklin","year":"2019","unstructured":"Guerreiro Stucklin, A. S. et al. Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas. Nat. Commun. 10, 4343 (2019).","journal-title":"Nat. Commun."},{"key":"1190_CR58","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/neuonc\/noab274","volume":"24","author":"F Doz","year":"2022","unstructured":"Doz, F. et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology 24, 997\u20131007 (2022).","journal-title":"Neuro-Oncology"},{"key":"1190_CR59","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer Genome Atlas Research Network.","year":"2008","unstructured":"Cancer Genome Atlas Research Network.Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061\u20131068 (2008).","journal-title":"Nature"},{"key":"1190_CR60","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1101\/gr.165126.113","volume":"24","author":"ZS Bao","year":"2014","unstructured":"Bao, Z. S. et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 24, 1765\u20131773 (2014).","journal-title":"Genome Res."},{"key":"1190_CR61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41016-023-00329-0","volume":"9","author":"Z Bao","year":"2023","unstructured":"Bao, Z. et al. PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II\/III trial. Chin. Neurosurg. J. 9, 21 (2023).","journal-title":"Chin. Neurosurg. J."},{"key":"1190_CR62","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat. Med. 29, 1103\u20131112 (2023).","journal-title":"Nat. Med."},{"key":"1190_CR63","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","volume":"36","author":"T Kaley","year":"2018","unstructured":"Kaley, T. et al. BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study. J. Clin. Oncol. 36, 3477\u20133484 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR64","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-23-3241","volume":"30","author":"KC Schreck","year":"2024","unstructured":"Schreck, K. C. et al. Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma. Clin. Cancer Res. 30, 2048\u20132056 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR65","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1158\/0008-5472.CAN-25-1301","volume":"86","author":"BT Kreger","year":"2026","unstructured":"Kreger, B. T. et al. CFT1946 is an orally available brain-penetrant BRAFV600-mutant degrader that overcomes BRAF inhibitor resistance. Cancer Res. 86, 438\u2013452 (2026).","journal-title":"Cancer Res."},{"key":"1190_CR66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1158\/1541-7786.MCR-06-0172","volume":"4","author":"GL Gallia","year":"2006","unstructured":"Gallia, G. L. et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol. Cancer Res. 4, 709\u2013714 (2006).","journal-title":"Mol. Cancer Res."},{"key":"1190_CR67","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","volume":"23","author":"SM Chang","year":"2005","unstructured":"Chang, S. M. et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23, 357\u2013361 (2005).","journal-title":"Invest. New Drugs"},{"key":"1190_CR68","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","volume":"22","author":"W Wick","year":"2016","unstructured":"Wick, W. et al. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin. Cancer Res. 22, 4797\u20134806 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR69","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/neuonc\/not247","volume":"16","author":"PY Wen","year":"2014","unstructured":"Wen, P. Y. et al. Phase I\/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology 16, 567\u2013578 (2014).","journal-title":"Neuro-Oncology"},{"key":"1190_CR70","first-page":"1270","volume":"17","author":"MW Pitz","year":"2015","unstructured":"Pitz, M. W. et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro-Oncology 17, 1270\u20131274 (2015).","journal-title":"Neuro-Oncology"},{"key":"1190_CR71","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/JCO.18.01207","volume":"37","author":"PY Wen","year":"2019","unstructured":"Wen, P. Y. et al. Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial. J. Clin. Oncol. 37, 741\u2013750 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108196","volume":"32","author":"S Xie","year":"2020","unstructured":"Xie, S. et al. Divergent roles of PI3K isoforms in PTEN-deficient glioblastomas. Cell Rep. 32, 108196 (2020).","journal-title":"Cell Rep."},{"key":"1190_CR73","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-19-2808","volume":"26","author":"PY Wen","year":"2020","unstructured":"Wen, P. Y. et al. First-in-human phase I study to evaluate the brain-penetrant PI3K\/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. Clin. Cancer Res. 26, 1820\u20131828 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR74","doi-asserted-by":"publisher","first-page":"LTBK","DOI":"10.1093\/neuonc\/noae165.1302","volume":"26","author":"IK Mellinghoff","year":"2024","unstructured":"Mellinghoff, I. K. et al. Evaluation of paxalisib In GBM agile phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. Neuro-Oncology 26, LTBK\u201302 (2024).","journal-title":"Neuro-Oncology"},{"key":"1190_CR75","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1093\/neuonc\/noad117","volume":"25","author":"EK Noch","year":"2023","unstructured":"Noch, E. K. et al. Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. Neuro-Oncology 25, 2165\u20132176 (2023).","journal-title":"Neuro-Oncology"},{"key":"1190_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf257","author":"KC Johnson","year":"2025","unstructured":"Johnson, K. C. et al. Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4\/6 and mTOR inhibition in a phase 0\/1 trial of recurrent high-grade glioma. Neuro-Oncology https:\/\/doi.org\/10.1093\/neuonc\/noaf257 (2025).","journal-title":"Neuro-Oncology"},{"key":"1190_CR77","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","volume":"140","author":"JW Taylor","year":"2018","unstructured":"Taylor, J. W. et al. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J. Neurooncol. 140, 477\u2013483 (2018).","journal-title":"J. Neurooncol."},{"key":"1190_CR78","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11060-019-03258-0","volume":"144","author":"TW Miller","year":"2019","unstructured":"Miller, T. W. et al. Tumor pharmacokinetics and pharmacodynamics of the CDK4\/6 inhibitor ribociclib in patients with recurrent glioblastoma. J. Neurooncol. 144, 563\u2013572 (2019).","journal-title":"J. Neurooncol."},{"key":"1190_CR79","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1200\/JCO.23.00493","volume":"41","author":"R Rahman","year":"2023","unstructured":"Rahman, R. et al. Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using bayesian adaptive randomization. J. Clin. Oncol. 41, 5524\u20135535 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR80","doi-asserted-by":"publisher","first-page":"viii110","DOI":"10.1093\/neuonc\/noae165.0425","volume":"26","author":"N Sanai","year":"2024","unstructured":"Sanai, N. et al. CTNI-58. A phase 0\/2 trial of abemaciclib plus ly3214996 in recurrent glioblastoma. Neuro-Oncology 26, viii110 (2024).","journal-title":"Neuro-Oncology"},{"key":"1190_CR81","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-17-0803","volume":"23","author":"I Olmez","year":"2017","unstructured":"Olmez, I. et al. Combined CDK4\/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms. Clin. Cancer Res. 23, 6958\u20136968 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR82","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1158\/0008-5472.CAN-17-3124","volume":"78","author":"I Olmez","year":"2018","unstructured":"Olmez, I. et al. Combined c-Met\/Trk inhibition overcomes resistance to CDK4\/6 inhibitors in glioblastoma. Cancer Res. 78, 4360\u20134369 (2018).","journal-title":"Cancer Res."},{"key":"1190_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.915862","volume":"12","author":"L Yin","year":"2022","unstructured":"Yin, L., Yao, Z., Wang, Y. & Mazuranic, M. Investigational cyclin-dependent kinase 4\/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models. Front. Oncol. 12, 915862 (2022).","journal-title":"Front. Oncol."},{"key":"1190_CR84","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov, G. V. et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214\u20131218 (2016).","journal-title":"Science"},{"key":"1190_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102264","volume":"52","author":"KJ Briggs","year":"2025","unstructured":"Briggs, K. J. et al. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers. Transl. Oncol. 52, 102264 (2025).","journal-title":"Transl. Oncol."},{"key":"1190_CR86","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/neuonc\/noae072","volume":"26","author":"R Rahman","year":"2024","unstructured":"Rahman, R. et al. DNA damage response in brain tumors: a Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. Neuro-Oncology 26, 1367\u20131387 (2024).","journal-title":"Neuro-Oncology"},{"key":"1190_CR87","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat1719","volume":"4","author":"ST Durant","year":"2018","unstructured":"Durant, S. T. et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci. Adv. 4, eaat1719 (2018).","journal-title":"Sci. Adv."},{"key":"1190_CR88","doi-asserted-by":"publisher","first-page":"viii88","DOI":"10.1093\/neuonc\/noae165.0349","volume":"26","author":"P Wen","year":"2024","unstructured":"Wen, P. et al. CTIM-16. Safety and Preliminary Efficacy of AZDd1390 + Radiation Therapy for Glioblastoma. Neuro-Oncology 26, viii88 (2024).","journal-title":"Neuro-Oncology"},{"key":"1190_CR89","doi-asserted-by":"publisher","first-page":"55555","DOI":"10.18632\/oncotarget.10864","volume":"7","author":"T Lan","year":"2016","unstructured":"Lan, T. et al. Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling. Oncotarget 7, 55555\u201355571 (2016).","journal-title":"Oncotarget"},{"key":"1190_CR90","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","volume":"17","author":"CR Timme","year":"2018","unstructured":"Timme, C. R., Rath, B. H., O\u2019Neill, J. W., Camphausen, K. & Tofilon, P. J. The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown in vitro and as orthotopic xenografts. Mol. Cancer Ther. 17, 1207\u20131216 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"1190_CR91","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 11, 80\u201391 (2021).","journal-title":"Cancer Discov."},{"key":"1190_CR92","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/1078-0432.CCR-24-2311","volume":"31","author":"EQ Lee","year":"2025","unstructured":"Lee, E. Q. et al. Phase I study of adavosertib with radiotherapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma. Clin. Cancer Res. 31, 983\u2013992 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-151","volume":"14","author":"L Tentori","year":"2014","unstructured":"Tentori, L. et al. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer 14, 151 (2014).","journal-title":"BMC Cancer"},{"key":"1190_CR94","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-24-2974","volume":"31","author":"D Stefan","year":"2025","unstructured":"Stefan, D. et al. Olaparib, temozolomide, and concomitant radiotherapy for partially resected or biopsy-only glioblastoma first-line treatment: results from the OLA-TMZ-RTE-01 phase I study. Clin. Cancer Res. 31, 1212\u20131222 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR95","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","volume":"22","author":"C Hanna","year":"2020","unstructured":"Hanna, C. et al. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology 22, 1840\u20131850 (2020).","journal-title":"Neuro-Oncology"},{"key":"1190_CR96","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.ijrobp.2024.01.011","volume":"118","author":"S Derby","year":"2024","unstructured":"Derby, S. et al. Concurrent olaparib and radiation therapy in older patients with newly diagnosed glioblastoma: the phase 1 dose-escalation paradigm trial. Int. J. Radiat. Oncol. Biol. Phys. 118, 1371\u20131378 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1190_CR97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.2005","author":"D Stefan","year":"2026","unstructured":"Stefan, D. et al. Phase 1\/2a study of concomitant radiotherapy with olaparib and temozolomide in unresectable high-grade glioma patients: final results from the phase 2a step (OLA-TMZ-RTE-01). J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.2005 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR98","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jamaoncol.2024.4361","volume":"10","author":"JN Sarkaria","year":"2024","unstructured":"Sarkaria, J. N. et al. Efficacy of adding veliparib to temozolomide for patients with MGMT-methylated glioblastoma: a randomized clinical trial. JAMA Oncol. 10, 1637\u20131644 (2024).","journal-title":"JAMA Oncol."},{"key":"1190_CR99","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/neuonc\/noaa016","volume":"22","author":"PA Baxter","year":"2020","unstructured":"Baxter, P. A. et al. A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. Neuro-Oncology 22, 875\u2013885 (2020).","journal-title":"Neuro-Oncology"},{"key":"1190_CR100","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","volume":"23","author":"HW Sim","year":"2021","unstructured":"Sim, H. W. et al. A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro-Oncology 23, 1736\u20131749 (2021).","journal-title":"Neuro-Oncology"},{"key":"1190_CR101","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3390\/curroncol32100541","volume":"32","author":"AF Piotrowski","year":"2025","unstructured":"Piotrowski, A. F. et al. Phase Ib\/II study of pamiparib plus radiation therapy and\/or temozolomide in adult patients with treatment-naive or recurrent\/refractory glioblastoma. Curr. Oncol. 32, 541 (2025).","journal-title":"Curr. Oncol."},{"key":"1190_CR102","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1126\/science.abn7570","volume":"377","author":"K Lin","year":"2022","unstructured":"Lin, K. et al. Mechanism-based design of agents that selectively target drug-resistant glioma. Science 377, 502\u2013511 (2022).","journal-title":"Science"},{"key":"1190_CR103","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat, M. et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580, 517\u2013523 (2020).","journal-title":"Nature"},{"key":"1190_CR104","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00401-023-02654-1","volume":"147","author":"S Hadad","year":"2023","unstructured":"Hadad, S. et al. De novo replication repair deficient glioblastoma, IDH-wildtype is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Acta Neuropathol. 147, 3 (2023).","journal-title":"Acta Neuropathol."},{"key":"1190_CR105","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/neuonc\/nov027","volume":"17","author":"EZ Erson-Omay","year":"2015","unstructured":"Erson-Omay, E. Z. et al. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology 17, 1356\u20131364 (2015).","journal-title":"Neuro-Oncology"},{"key":"1190_CR106","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00525","volume":"7","author":"PR Benusiglio","year":"2023","unstructured":"Benusiglio, P. R. et al. Mismatch repair deficiency and lynch syndrome among adult patients with glioma. JCO Precis. Oncol. 7, e2200525 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"1190_CR107","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41588-025-02420-x","volume":"58","author":"NR Fernandez","year":"2026","unstructured":"Fernandez, N. R. et al. Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma. Nat. Genet. 58, 132\u2013142 (2026).","journal-title":"Nat. Genet."},{"key":"1190_CR108","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/0092-8674(85)90170-9","volume":"43","author":"CW Greider","year":"1985","unstructured":"Greider, C. W. & Blackburn, E. H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43, 405\u2013413 (1985).","journal-title":"Cell"},{"key":"1190_CR109","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0092-8674(00)80538-3","volume":"90","author":"M Meyerson","year":"1997","unstructured":"Meyerson, M. et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785\u2013795 (1997).","journal-title":"Cell"},{"key":"1190_CR110","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957\u2013959 (2013).","journal-title":"Science"},{"key":"1190_CR111","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1126\/science.aab0015","volume":"348","author":"RJ Bell","year":"2015","unstructured":"Bell, R. J. et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348, 1036\u20131039 (2015).","journal-title":"Science"},{"key":"1190_CR112","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1073\/pnas.1303607110","volume":"110","author":"PJ Killela","year":"2013","unstructured":"Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl Acad. Sci. USA 110, 6021\u20136026 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1190_CR113","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/annonc\/mdu550","volume":"26","author":"AA Chiappori","year":"2015","unstructured":"Chiappori, A. A. et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann. Oncol. 26, 354\u2013362 (2015).","journal-title":"Ann. Oncol."},{"key":"1190_CR114","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1056\/NEJMoa1503479","volume":"373","author":"GM Baerlocher","year":"2015","unstructured":"Baerlocher, G. M., Burington, B. & Snyder, D. S. Telomerase inhibitor imetelstat in essential thrombocythemia and myelofibrosis. N. Engl. J. Med. 373, 2580 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR115","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41586-021-03415-4","volume":"593","author":"GE Ghanim","year":"2021","unstructured":"Ghanim, G. E. et al. Structure of human telomerase holoenzyme with bound telomeric DNA. Nature 593, 449\u2013453 (2021).","journal-title":"Nature"},{"key":"1190_CR116","doi-asserted-by":"publisher","first-page":"ii237","DOI":"10.1093\/neuonc\/noaa215.988","volume":"22","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Ltbk-01. INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. Neuro-Oncology 22, ii237 (2020).","journal-title":"Neuro-Oncology"},{"key":"1190_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018588","volume":"6","author":"R Villalonga-Planells","year":"2011","unstructured":"Villalonga-Planells, R. et al. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 6, e18588 (2011).","journal-title":"PLoS One"},{"key":"1190_CR118","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn6274","volume":"17","author":"V Rendo","year":"2025","unstructured":"Rendo, V. et al. A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma. Sci. Transl. Med. 17, eadn6274 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1190_CR119","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/neuonc\/nox161","volume":"20","author":"E Galanis","year":"2018","unstructured":"Galanis, E. et al. Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02. Neuro-Oncology 20, 546\u2013556 (2018).","journal-title":"Neuro-Oncology"},{"key":"1190_CR120","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/neuonc\/noaa062","volume":"22","author":"VK Puduvalli","year":"2020","unstructured":"Puduvalli, V. K. et al. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro-Oncology 22, 1505\u20131515 (2020).","journal-title":"Neuro-Oncology"},{"key":"1190_CR121","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/neuonc\/nou350","volume":"17","author":"EQ Lee","year":"2015","unstructured":"Lee, E. Q. et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro-Oncology 17, 862\u2013867 (2015).","journal-title":"Neuro-Oncology"},{"key":"1190_CR122","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/s41588-024-01880-x","volume":"56","author":"HJ Jang","year":"2024","unstructured":"Jang, H. J. et al. Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells. Nat. Genet. 56, 1903\u20131913 (2024).","journal-title":"Nat. Genet."},{"key":"1190_CR123","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41586-023-05968-y","volume":"618","author":"R Mancusi","year":"2023","unstructured":"Mancusi, R. & Monje, M. The neuroscience of cancer. Nature 618, 467\u2013479 (2023).","journal-title":"Nature"},{"key":"1190_CR124","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","volume":"186","author":"F Winkler","year":"2023","unstructured":"Winkler, F. et al. Cancer neuroscience: state of the field, emerging directions. Cell 186, 1689\u20131707 (2023).","journal-title":"Cell"},{"key":"1190_CR125","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/2159-8290.CD-24-0194","volume":"15","author":"V Venkataramani","year":"2025","unstructured":"Venkataramani, V. et al. Cancer neuroscience of brain tumors: from multicellular networks to neuroscience-instructed cancer therapies. Cancer Discov. 15, 39\u201351 (2025).","journal-title":"Cancer Discov."},{"key":"1190_CR126","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","volume":"185","author":"V Venkataramani","year":"2022","unstructured":"Venkataramani, V. et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell 185, 2899\u20132917.e31 (2022).","journal-title":"Cell"},{"key":"1190_CR127","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","volume":"573","author":"V Venkataramani","year":"2019","unstructured":"Venkataramani, V. et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573, 532\u2013538 (2019).","journal-title":"Nature"},{"key":"1190_CR128","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","volume":"573","author":"HS Venkatesh","year":"2019","unstructured":"Venkatesh, H. S. et al. Electrical and synaptic integration of glioma into neural circuits. Nature 573, 539\u2013545 (2019).","journal-title":"Nature"},{"key":"1190_CR129","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.cell.2015.04.012","volume":"161","author":"HS Venkatesh","year":"2015","unstructured":"Venkatesh, H. S. et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell 161, 803\u2013816 (2015).","journal-title":"Cell"},{"key":"1190_CR130","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03580-6","volume":"594","author":"Y Pan","year":"2021","unstructured":"Pan, Y. et al. NF1 mutation drives neuronal activity-dependent initiation of optic glioma. Nature 594, 277\u2013282 (2021).","journal-title":"Nature"},{"key":"1190_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15132","volume":"8","author":"P Hasel","year":"2017","unstructured":"Hasel, P. et al. Neurons and neuronal activity control gene expression in astrocytes to regulate their development and metabolism. Nat. Commun. 8, 15132 (2017).","journal-title":"Nat. Commun."},{"key":"1190_CR132","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0896-6273(92)90271-E","volume":"8","author":"JW Dani","year":"1992","unstructured":"Dani, J. W., Chernjavsky, A. & Smith, S. J. Neuronal activity triggers calcium waves in hippocampal astrocyte networks. Neuron 8, 429\u2013440 (1992).","journal-title":"Neuron"},{"key":"1190_CR133","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","volume":"528","author":"M Osswald","year":"2015","unstructured":"Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93\u201398 (2015).","journal-title":"Nature"},{"key":"1190_CR134","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/neuonc\/nox070","volume":"19","author":"S Weil","year":"2017","unstructured":"Weil, S. et al. Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas. Neuro-Oncology 19, 1316\u20131326 (2017).","journal-title":"Neuro-Oncology"},{"key":"1190_CR135","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41586-022-05520-4","volume":"613","author":"D Hausmann","year":"2023","unstructured":"Hausmann, D. et al. Autonomous rhythmic activity in glioma networks drives brain tumour growth. Nature 613, 179\u2013186 (2023).","journal-title":"Nature"},{"key":"1190_CR136","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1016\/j.cell.2026.03.018","volume":"189","author":"F Winkler","year":"2026","unstructured":"Winkler, F. et al. Cancer neuroscience: the past, the present, and the road ahead. Cell 189, 2464\u20132489 https:\/\/doi.org\/10.1016\/j.cell.2026.03.018 (2026).","journal-title":"Cell"},{"key":"1190_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11846-1","volume":"24","author":"S Heuer","year":"2024","unstructured":"Heuer, S. et al. PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma. BMC Cancer 24, 135 (2024).","journal-title":"BMC Cancer"},{"key":"1190_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11797-z","volume":"24","author":"M Mastall","year":"2024","unstructured":"Mastall, M. et al. A phase Ib\/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC Cancer 24, 82 (2024).","journal-title":"BMC Cancer"},{"key":"1190_CR139","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nature24014","volume":"549","author":"HS Venkatesh","year":"2017","unstructured":"Venkatesh, H. S. et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature 549, 533\u2013537 (2017).","journal-title":"Nature"},{"key":"1190_CR140","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/neuonc\/noab092","volume":"23","author":"M Schneider","year":"2021","unstructured":"Schneider, M. et al. Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. Neuro-Oncology 23, 1885\u20131897 (2021).","journal-title":"Neuro-Oncology"},{"key":"1190_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05977-0","volume":"23","author":"T Zeyen","year":"2022","unstructured":"Zeyen, T. et al. Phase I\/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth\/NOA-24 trial. Trials 23, 57 (2022).","journal-title":"Trials"},{"key":"1190_CR142","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2174\/1570159X15666170630164226","volume":"16","author":"BM Brown","year":"2018","unstructured":"Brown, B. M., Pressley, B. & Wulff, H. KCa3.1 channel modulators as potential therapeutic compounds for glioblastoma. Curr. Neuropharmacol. 16, 618\u2013626 (2018).","journal-title":"Curr. Neuropharmacol."},{"key":"1190_CR143","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s43018-025-01097-9","volume":"7","author":"PM Moreno-Sanchez","year":"2026","unstructured":"Moreno-Sanchez, P. M., Rezaeipour, M., Inderberg, E. M., Platten, M. & Golebiewska, A. Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity. Nat. Cancer 7, 29\u201342 (2026).","journal-title":"Nat. Cancer"},{"key":"1190_CR144","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-025-01227-5","volume":"26","author":"J Mahdi","year":"2026","unstructured":"Mahdi, J., Trivedi, V. & Monje, M. The promise of immunotherapy for central nervous system tumours. Nat. Rev. Immunol. 26, 213\u2013229 (2026).","journal-title":"Nat. Rev. Immunol."},{"key":"1190_CR145","doi-asserted-by":"publisher","first-page":"eads0449","DOI":"10.1126\/sciimmunol.ads0449","volume":"10","author":"L Bunse","year":"2025","unstructured":"Bunse, L., Bunse, T., Kilian, M., Quintana, F. J. & Platten, M. The immunology of brain tumors. Sci. Immunol. 10, eads0449 https:\/\/doi.org\/10.1126\/sciimmunol.ads0449 (2025).","journal-title":"Sci. Immunol."},{"key":"1190_CR146","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1745-6150-7-21","volume":"7","author":"S Kim","year":"2012","unstructured":"Kim, S., Kon, M. & DeLisi, C. Pathway-based classification of cancer subtypes. Biol. Direct 7, 21 (2012).","journal-title":"Biol. Direct"},{"key":"1190_CR147","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-021-01360-7","volume":"125","author":"A Lasorella","year":"2021","unstructured":"Lasorella, A. & Iavarone, A. The making of the glioblastoma classification. Br. J. Cancer 125, 4\u20136 (2021).","journal-title":"Br. J. Cancer"},{"key":"1190_CR148","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s43018-020-00159-4","volume":"2","author":"L Garofano","year":"2021","unstructured":"Garofano, L. et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat. Cancer 2, 141\u2013156 (2021).","journal-title":"Nat. Cancer"},{"key":"1190_CR149","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s43018-022-00510-x","volume":"4","author":"S Migliozzi","year":"2023","unstructured":"Migliozzi, S. et al. Integrative multi-omics networks identify PKC\u03b4 and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. Nat. Cancer 4, 181\u2013202 (2023).","journal-title":"Nat. Cancer"},{"key":"1190_CR150","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ccell.2023.12.015","volume":"42","author":"KH Kim","year":"2024","unstructured":"Kim, K. H. et al. Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell 42, 358\u2013377.e8 (2024).","journal-title":"Cancer Cell"},{"key":"1190_CR151","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.ccell.2025.08.009","volume":"43","author":"S Migliozzi","year":"2025","unstructured":"Migliozzi, S. et al. Restraint of cancer cell plasticity by spatial homotypic clustering. Cancer Cell 43, 2206\u20132223.e10 (2025).","journal-title":"Cancer Cell"},{"key":"1190_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41559-1","volume":"14","author":"LS Hu","year":"2023","unstructured":"Hu, L. S. et al. Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. Nat. Commun. 14, 6066 (2023).","journal-title":"Nat. Commun."},{"key":"1190_CR153","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature08712","volume":"463","author":"MS Carro","year":"2010","unstructured":"Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318\u2013325 (2010).","journal-title":"Nature"},{"key":"1190_CR154","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/1535-7163.MCT-11-0048","volume":"10","author":"ME Hegi","year":"2011","unstructured":"Hegi, M. E. et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib \u2014 a phase II trial. Mol. Cancer Ther. 10, 1102\u20131112 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"1190_CR155","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adv2881","volume":"17","author":"AL Ling","year":"2025","unstructured":"Ling, A. L. et al. Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Sci. Transl. Med. 17, eadv2881 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1190_CR156","doi-asserted-by":"publisher","first-page":"7841","DOI":"10.1158\/1078-0432.CCR-05-0421","volume":"11","author":"AB Lassman","year":"2005","unstructured":"Lassman, A. B. et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Cancer Res. 11, 7841\u20137850 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR157","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","volume":"2","author":"I Vivanco","year":"2012","unstructured":"Vivanco, I. et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2, 458\u2013471 (2012).","journal-title":"Cancer Discov."},{"key":"1190_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07334-3","volume":"9","author":"EC Randall","year":"2018","unstructured":"Randall, E. C. et al. Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nat. Commun. 9, 4904 (2018).","journal-title":"Nat. Commun."},{"key":"1190_CR159","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/neuonc\/not116","volume":"15","author":"RK Balvers","year":"2013","unstructured":"Balvers, R. K. et al. Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules. Neuro-Oncology 15, 1684\u20131695 (2013).","journal-title":"Neuro-Oncology"},{"key":"1190_CR160","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380\u20132388 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR161","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711\u20131723 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR162","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1158\/1078-0432.CCR-08-3328","volume":"16","author":"HJ Ross","year":"2010","unstructured":"Ross, H. J. et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin. Cancer Res. 16, 1938\u20131949 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR163","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/cancers10120489","volume":"10","author":"Y Gao","year":"2018","unstructured":"Gao, Y., Vallentgoed, W. R. & French, P. J. Finding the right way to target EGFR in glioblastomas; lessons from lung adenocarcinomas. Cancers 10, 489 (2018).","journal-title":"Cancers"},{"key":"1190_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1323350","volume":"13","author":"D Ribatti","year":"2023","unstructured":"Ribatti, D., Annese, T. & Tamma, R. Vascular co-option in resistance to anti-angiogenic therapy. Front. Oncol. 13, 1323350 (2023).","journal-title":"Front. Oncol."},{"key":"1190_CR165","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550\u2013563 (2016).","journal-title":"Cell"},{"key":"1190_CR166","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807\u20131812 (2008).","journal-title":"Science"},{"key":"1190_CR167","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ng.3273","volume":"47","author":"H Suzuki","year":"2015","unstructured":"Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47, 458\u2013468 (2015).","journal-title":"Nat. Genet."},{"key":"1190_CR168","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1190_CR169","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","volume":"52","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat. Genet. 52, 891\u2013897 (2020).","journal-title":"Nat. Genet."},{"key":"1190_CR170","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12832","author":"DN Louis","year":"2020","unstructured":"Louis, D. N. et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. https:\/\/doi.org\/10.1111\/bpa.12832 (2020).","journal-title":"Brain Pathol."},{"key":"1190_CR171","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JCO.19.00367","volume":"38","author":"K Draaisma","year":"2020","unstructured":"Draaisma, K. et al. Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study. J. Clin. Oncol. 38, 81\u201399 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR172","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00401-018-1842-y","volume":"135","author":"FP Barthel","year":"2018","unstructured":"Barthel, F. P., Wesseling, P. & Verhaak, R. G. W. Reconstructing the molecular life history of gliomas. Acta Neuropathol. 135, 649\u2013670 (2018).","journal-title":"Acta Neuropathol."},{"key":"1190_CR173","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1101\/gr.180612.114","volume":"25","author":"H Kim","year":"2015","unstructured":"Kim, H. et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 25, 316\u2013327 (2015).","journal-title":"Genome Res."},{"key":"1190_CR174","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849.e21 (2019).","journal-title":"Cell"},{"key":"1190_CR175","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"1190_CR176","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","volume":"187","author":"R Mathur","year":"2024","unstructured":"Mathur, R. et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell 187, 446\u2013463.e16 (2024).","journal-title":"Cell"},{"key":"1190_CR177","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/neuonc\/noab231","volume":"24","author":"Y Hoogstrate","year":"2022","unstructured":"Hoogstrate, Y. et al. The EGFRvIII transcriptome in glioblastoma: a meta-omics analysis. Neuro-Oncology 24, 429\u2013441 (2022).","journal-title":"Neuro-Oncology"},{"key":"1190_CR178","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306309","volume":"11","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors. Adv. Sci. 11, e2306309 (2024).","journal-title":"Adv. Sci."},{"key":"1190_CR179","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau, B. B. et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 20, 233\u2013246.e7 (2017).","journal-title":"Cell Stem Cell"},{"key":"1190_CR180","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41588-024-01920-6","volume":"56","author":"JS Schiffman","year":"2024","unstructured":"Schiffman, J. S. et al. Defining heritability, plasticity, and transition dynamics of cellular phenotypes in somatic evolution. Nat. Genet. 56, 2174\u20132184 (2024).","journal-title":"Nat. Genet."},{"key":"1190_CR181","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41589-020-00716-z","volume":"17","author":"G Schutzius","year":"2021","unstructured":"Schutzius, G. et al. BET bromodomain inhibitors regulate keratinocyte plasticity. Nat. Chem. Biol. 17, 280\u2013290 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"1190_CR182","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf169","author":"R Vadla","year":"2025","unstructured":"Vadla, R. et al. BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma. Neuro-Oncology https:\/\/doi.org\/10.1093\/neuonc\/noaf169 (2025).","journal-title":"Neuro-Oncology"},{"key":"1190_CR183","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41392-022-01176-8","volume":"7","author":"L Yang","year":"2022","unstructured":"Yang, L. et al. Extrachromosomal circular DNA: biogenesis, structure, functions and diseases. Signal. Transduct. Target. Ther. 7, 342 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1190_CR184","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccell.2021.03.006","volume":"39","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription. Cancer Cell 39, 694\u2013707.e7 (2021).","journal-title":"Cancer Cell"},{"key":"1190_CR185","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41586-019-1763-5","volume":"575","author":"S Wu","year":"2019","unstructured":"Wu, S. et al. Circular ecDNA promotes accessible chromatin and high oncogene expression. Nature 575, 699\u2013703 (2019).","journal-title":"Nature"},{"key":"1190_CR186","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07861-8","volume":"635","author":"KL Hung","year":"2024","unstructured":"Hung, K. L. et al. Coordinated inheritance of extrachromosomal DNAs in cancer cells. Nature 635, 201\u2013209 (2024).","journal-title":"Nature"},{"key":"1190_CR187","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41588-022-01177-x","volume":"54","author":"JT Lange","year":"2022","unstructured":"Lange, J. T. et al. The evolutionary dynamics of extrachromosomal DNA in human cancers. Nat. Genet. 54, 1527\u20131533 (2022).","journal-title":"Nat. Genet."},{"key":"1190_CR188","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41588-024-01949-7","volume":"56","author":"H Kim","year":"2024","unstructured":"Kim, H. et al. Mapping extrachromosomal DNA amplifications during cancer progression. Nat. Genet. 56, 2447\u20132454 (2024).","journal-title":"Nat. Genet."},{"key":"1190_CR189","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41573-025-01369-0","volume":"25","author":"ITL Wong","year":"2026","unstructured":"Wong, I. T. L. et al. Targeting extrachromosomal DNA in human cancers. Nat. Rev. Drug Discov. 25, 375\u2013389 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1190_CR190","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.1114033109","volume":"109","author":"NJ Szerlip","year":"2012","unstructured":"Szerlip, N. J. et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl Acad. Sci. USA 109, 3041\u20133046 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1190_CR191","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12393","author":"HK Gan","year":"2013","unstructured":"Gan, H. K., Cvrljevic, A. N. & Johns, T. G. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. https:\/\/doi.org\/10.1111\/febs.12393 (2013).","journal-title":"FEBS J."},{"key":"1190_CR192","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab231","author":"Y Hoogstrate","year":"2021","unstructured":"Hoogstrate, Y. et al. The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis. Neuro-Oncology https:\/\/doi.org\/10.1093\/neuonc\/noab231 (2021).","journal-title":"Neuro-Oncology"},{"key":"1190_CR193","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1158\/1078-0432.CCR-11-3084","volume":"18","author":"A Schulte","year":"2012","unstructured":"Schulte, A. et al. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Clin. Cancer Res. 18, 1901\u20131913 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR194","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-024-07802-5","volume":"635","author":"J Tang","year":"2024","unstructured":"Tang, J. et al. Enhancing transcription-replication conflict targets ecDNA-positive cancers. Nature 635, 210\u2013218 (2024).","journal-title":"Nature"},{"key":"1190_CR195","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/ng.3590","volume":"48","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768\u2013776 (2016).","journal-title":"Nat. Genet."},{"key":"1190_CR196","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccell.2015.07.013","volume":"28","author":"J Kim","year":"2015","unstructured":"Kim, J. et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28, 318\u2013328 (2015).","journal-title":"Cancer Cell"},{"key":"1190_CR197","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","volume":"185","author":"FS Varn","year":"2022","unstructured":"Varn, F. S. et al. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 185, 2184\u20132199.e16 (2022).","journal-title":"Cell"},{"key":"1190_CR198","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae214","author":"CG Lucas","year":"2024","unstructured":"Lucas, C. G. et al. Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro-Oncology https:\/\/doi.org\/10.1093\/neuonc\/noae214 (2024).","journal-title":"Neuro-Oncology"},{"key":"1190_CR199","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh4181","volume":"15","author":"Q Mu","year":"2023","unstructured":"Mu, Q. et al. Identifying predictors of glioma evolution from longitudinal sequencing. Sci. Transl. Med. 15, eadh4181 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1190_CR200","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.stem.2017.06.004","volume":"21","author":"NI Park","year":"2017","unstructured":"Park, N. I. et al. ASCL1 reorganizes chromatin to direct neuronal fate and suppress tumorigenicity of glioblastoma stem cells. Cell Stem Cell 21, 209\u2013224.e7 (2017).","journal-title":"Cell Stem Cell"},{"key":"1190_CR201","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood.2024024008","volume":"145","author":"GC Issa","year":"2025","unstructured":"Issa, G. C., Stein, E. M. & DiNardo, C. D. How I treat acute myeloid leukemia with differentiation therapy. Blood 145, 1251\u20131259 (2025).","journal-title":"Blood"},{"key":"1190_CR202","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1158\/0008-5472.CAN-14-3122","volume":"75","author":"S Klingler","year":"2015","unstructured":"Klingler, S. et al. Development of resistance to EGFR-targeted therapy in malignant glioma can occur through EGFR-dependent and -independent mechanisms. Cancer Res. 75, 2109\u20132119 (2015).","journal-title":"Cancer Res."},{"key":"1190_CR203","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1101\/gad.324301.119","volume":"33","author":"RC Gimple","year":"2019","unstructured":"Gimple, R. C., Bhargava, S., Dixit, D. & Rich, J. N. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev. 33, 591\u2013609 (2019).","journal-title":"Genes Dev."},{"key":"1190_CR204","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.3390\/ijms23094602","volume":"23","author":"SMB Rodriguez","year":"2022","unstructured":"Rodriguez, S. M. B. et al. Glioblastoma stem cells-useful tools in the battle against cancer. Int. J. Mol. Sci. 23, 4602 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1190_CR205","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","volume":"6","author":"BC Prager","year":"2020","unstructured":"Prager, B. C., Bhargava, S., Mahadev, V., Hubert, C. G. & Rich, J. N. Glioblastoma stem cells: driving resilience through chaos. Trends Cancer 6, 223\u2013235 (2020).","journal-title":"Trends Cancer"},{"key":"1190_CR206","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51270-1","volume":"9","author":"R Sachdeva","year":"2019","unstructured":"Sachdeva, R. et al. BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma. Sci. Rep. 9, 14569 (2019).","journal-title":"Sci. Rep."},{"key":"1190_CR207","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821\u20135828 (2003).","journal-title":"Cancer Res."},{"key":"1190_CR208","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3892\/ijo.2021.5225","volume":"59","author":"J Jin","year":"2021","unstructured":"Jin, J., Grigore, F., Chen, C. C. & Li, M. Self-renewal signaling pathways and differentiation therapies of glioblastoma stem cells (Review). Int. J. Oncol. 59, 45 (2021).","journal-title":"Int. J. Oncol."},{"key":"1190_CR209","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/cells15050413","volume":"15","author":"K Salmeron-Moreno","year":"2026","unstructured":"Salmeron-Moreno, K. et al. Neuro-oncological perspectives on cancer stem cell biology in glioblastoma: implications for resection, recurrence, targeted therapy, and other CNS tumors. Cells 15, 413 (2026).","journal-title":"Cells"},{"key":"1190_CR210","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2159-8290.CD-23-1510","volume":"14","author":"G Gargiulo","year":"2024","unstructured":"Gargiulo, G., Serresi, M. & Marine, J. C. Cell states in cancer: drivers, passengers, and trailers. Cancer Discov. 14, 610\u2013614 (2024).","journal-title":"Cancer Discov."},{"key":"1190_CR211","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu, D. et al. The blood-brain barrier: structure, regulation, and drug delivery. Signal. Transduct. Target. Ther. 8, 217 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1190_CR212","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria, J. N. et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology 20, 184\u2013191 (2018).","journal-title":"Neuro-Oncology"},{"key":"1190_CR213","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","volume":"11","author":"Z Konteatis","year":"2020","unstructured":"Konteatis, Z. et al. Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Med. Chem. Lett. 11, 101\u2013107 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"1190_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166967","volume":"1870","author":"JCS Chaves","year":"2024","unstructured":"Chaves, J. C. S., Dando, S. J., White, A. R. & Oikari, L. E. Blood-brain barrier transporters: an overview of function, dysfunction in Alzheimer\u2019s disease and strategies for treatment. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 166967 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1190_CR215","first-page":"1158","volume":"22","author":"H Amawi","year":"2025","unstructured":"Amawi, H. et al. Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer. Cancer Biol. Med. 22, 1158\u20131180 (2025).","journal-title":"Cancer Biol. Med."},{"key":"1190_CR216","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14737159.2026.2656353","volume":"26","author":"M Shevtsov","year":"2026","unstructured":"Shevtsov, M. et al. What is the future of nanoparticles as a clinical theranostic tool for glioblastoma? Expert Rev. Mol. Diagn. 26, 201\u2013222 (2026).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"1190_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-026-00538-9","volume":"26","author":"Y Lei","year":"2026","unstructured":"Lei, Y., Xiao, T., Hu, X. & Lin, H. Advanced drug delivery strategies for overcoming biological barriers: tumor microenvironment and blood-brain barrier. Drugs R. D. 26, 1\u201330 (2026).","journal-title":"Drugs R. D."},{"key":"1190_CR218","volume":"6","author":"C Dmello","year":"2024","unstructured":"Dmello, C. et al. Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma. Neurooncol. Adv. 6, vdae186 (2024).","journal-title":"Neurooncol. Adv."},{"key":"1190_CR219","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41694-9","volume":"14","author":"I Noorani","year":"2023","unstructured":"Noorani, I. & de la Rosa, J. Breaking barriers for glioblastoma with a path to enhanced drug delivery. Nat. Commun. 14, 5909 (2023).","journal-title":"Nat. Commun."},{"key":"1190_CR220","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11060-024-04795-z","volume":"170","author":"H Zhu","year":"2024","unstructured":"Zhu, H., Allwin, C., Bassous, M. G. & Pouliopoulos, A. N. Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials. J. Neurooncol. 170, 235\u2013252 (2024).","journal-title":"J. Neurooncol."},{"key":"1190_CR221","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ultrasmedbio.2004.04.010","volume":"30","author":"N Sheikov","year":"2004","unstructured":"Sheikov, N., McDannold, N., Vykhodtseva, N., Jolesz, F. & Hynynen, K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med. Biol. 30, 979\u2013989 (2004).","journal-title":"Ultrasound Med. Biol."},{"key":"1190_CR222","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/pharmaceutics14040833","volume":"14","author":"K Gandhi","year":"2022","unstructured":"Gandhi, K., Barzegar-Fallah, A., Banstola, A., Rizwan, S. B. & Reynolds, J. N. J. Ultrasound-mediated blood-brain barrier disruption for drug delivery: a systematic review of protocols, efficacy, and safety outcomes from preclinical and clinical studies. Pharmaceutics 14, 833 (2022).","journal-title":"Pharmaceutics"},{"key":"1190_CR223","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-18-3643","volume":"25","author":"A Idbaih","year":"2019","unstructured":"Idbaih, A. et al. Safety and feasibility of repeated and transient blood-brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma. Clin. Cancer Res. 25, 3793\u20133801 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR224","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend, A. M. et al. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 24, 509\u2013522 (2023).","journal-title":"Lancet Oncol."},{"key":"1190_CR225","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103280118","volume":"118","author":"P Anastasiadis","year":"2021","unstructured":"Anastasiadis, P. et al. Localized blood-brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions-controlled focused ultrasound. Proc. Natl Acad. Sci. USA 118, e2103280118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1190_CR226","doi-asserted-by":"publisher","first-page":"343re342","DOI":"10.1126\/scitranslmed.aaf6086","volume":"8","author":"A Carpentier","year":"2016","unstructured":"Carpentier, A. et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci. Transl. Med. 8, 343re342 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1190_CR227","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45818-7","volume":"15","author":"A Carpentier","year":"2024","unstructured":"Carpentier, A. et al. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial. Nat. Commun. 15, 1650 (2024).","journal-title":"Nat. Commun."},{"key":"1190_CR228","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36340-0","volume":"9","author":"T Mainprize","year":"2019","unstructured":"Mainprize, T. et al. Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study. Sci. Rep. 9, 321 (2019).","journal-title":"Sci. Rep."},{"key":"1190_CR229","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(25)00492-9","volume":"26","author":"GF Woodworth","year":"2025","unstructured":"Woodworth, G. F. et al. Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 26, 1651\u20131664 (2025).","journal-title":"Lancet Oncol."},{"key":"1190_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fnimg.2023.1062493","volume":"2","author":"E Szychot","year":"2023","unstructured":"Szychot, E. et al. Evaluating drug distribution in children and young adults with diffuse midline glioma of the pons (DIPG) treated with convection-enhanced drug delivery. Front. Neuroimaging 2, 1062493 (2023).","journal-title":"Front. Neuroimaging"},{"key":"1190_CR231","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/neuonc\/noaa149","volume":"22","author":"MA Vogelbaum","year":"2020","unstructured":"Vogelbaum, M. A. et al. Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro-Oncology 22, 1568\u20131579 (2020).","journal-title":"Neuro-Oncology"},{"key":"1190_CR232","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","volume":"29","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff, I. K. et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat. Med. 29, 615\u2013622 (2023).","journal-title":"Nat. Med."},{"key":"1190_CR233","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K., Anami, Y., Ha, S. Y. Y. & Yamazaki, C. M. Exploring the next generation of antibody-drug conjugates. Nat. Rev. Clin. Oncol. 21, 203\u2013223 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1190_CR234","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","volume":"20","author":"MJ Mair","year":"2023","unstructured":"Mair, M. J. et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. Nat. Rev. Clin. Oncol. 20, 372\u2013389 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1190_CR235","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch, R. et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat. Med. 28, 1840\u20131847 (2022).","journal-title":"Nat. Med."},{"key":"1190_CR236","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck, N. et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat. Med. 30, 3717\u20133727 (2024).","journal-title":"Nat. Med."},{"key":"1190_CR237","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/neuonc\/noz222","volume":"22","author":"M Van Den Bent","year":"2020","unstructured":"Van Den Bent, M. et al. INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-Oncology 22, 684\u2013693 (2020).","journal-title":"Neuro-Oncology"},{"key":"1190_CR238","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/neuonc\/noad205","volume":"26","author":"S Coy","year":"2024","unstructured":"Coy, S. et al. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro-Oncology 26, 458\u2013472 (2024).","journal-title":"Neuro-Oncology"},{"key":"1190_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115489","volume":"257","author":"Y Mao","year":"2023","unstructured":"Mao, Y. et al. Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma. Eur. J. Med. Chem. 257, 115489 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1190_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54138-9","volume":"15","author":"EG Fernandez","year":"2024","unstructured":"Fernandez, E. G. et al. Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma. Nat. Commun. 15, 10089 (2024).","journal-title":"Nat. Commun."},{"key":"1190_CR241","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117657","volume":"102","author":"D Li","year":"2024","unstructured":"Li, D. et al. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy. Bioorg Med. Chem. 102, 117657 (2024).","journal-title":"Bioorg Med. Chem."},{"key":"1190_CR242","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.100982","volume":"50","author":"S Uchida","year":"2024","unstructured":"Uchida, S. et al. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma. Neoplasia 50, 100982 (2024).","journal-title":"Neoplasia"},{"key":"1190_CR243","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/1878-0261.13453","volume":"17","author":"B Dufrusine","year":"2023","unstructured":"Dufrusine, B. et al. Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma. Mol. Oncol. 17, 1460\u20131473 (2023).","journal-title":"Mol. Oncol."},{"key":"1190_CR244","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/ph15070837","volume":"15","author":"T Anzai","year":"2022","unstructured":"Anzai, T. et al. Identification of CD73 as the antigen of an antigen-unknown monoclonal antibody established by exosome immunization, and its antibody-drug conjugate exerts an antitumor effect on glioblastoma cell lines. Pharmaceuticals 15, 837 (2022).","journal-title":"Pharmaceuticals"},{"key":"1190_CR245","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1093\/neuonc\/noae125","volume":"26","author":"M Weller","year":"2024","unstructured":"Weller, M. et al. Targeted radionuclide therapy for gliomas: emerging clinical trial landscape. Neuro-Oncology 26, S208\u2013S214 (2024).","journal-title":"Neuro-Oncology"},{"key":"1190_CR246","volume":"6","author":"J Pichler","year":"2024","unstructured":"Pichler, J. et al. Results from a phase I study of 4-l-[131I]iodo-phenylalanine ([131I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1). Neurooncol. Adv. 6, vdae130 (2024).","journal-title":"Neurooncol. Adv."},{"key":"1190_CR247","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/cancers16091715","volume":"16","author":"AR Hoggarth","year":"2024","unstructured":"Hoggarth, A. R. et al. Clinical theranostics in recurrent gliomas: a review. Cancers 16, 1715 (2024).","journal-title":"Cancers"},{"key":"1190_CR248","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/1878-0261.12997","volume":"15","author":"C Alix-Panabieres","year":"2021","unstructured":"Alix-Panabieres, C. & Pantel, K. Liquid biopsy: from discovery to clinical implementation. Mol. Oncol. 15, 1617\u20131621 (2021).","journal-title":"Mol. Oncol."},{"key":"1190_CR249","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/neuonc\/noac004","volume":"24","author":"R Soffietti","year":"2022","unstructured":"Soffietti, R. et al. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro-Oncology 24, 855\u2013871 (2022).","journal-title":"Neuro-Oncology"},{"key":"1190_CR250","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","volume":"565","author":"AM Miller","year":"2019","unstructured":"Miller, A. M. et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature 565, 654\u2013658 (2019).","journal-title":"Nature"},{"key":"1190_CR251","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s40478-024-01846-4","volume":"12","author":"RA Hickman","year":"2024","unstructured":"Hickman, R. A. et al. Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors. Acta Neuropathol. Commun. 12, 151 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"1190_CR252","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1016\/S1470-2045(24)00190-6","volume":"25","author":"KM Hotchkiss","year":"2024","unstructured":"Hotchkiss, K. M. et al. A brave new framework for glioma drug development. Lancet Oncol. 25, e512\u2013e519 (2024).","journal-title":"Lancet Oncol."},{"key":"1190_CR253","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01102-1","volume":"14","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas, E., Tsimberidou, A. M., Vo, H. H. & Kurzrock, R. Clinical trial design in the era of precision medicine. Genome Med. 14, 101 (2022).","journal-title":"Genome Med."},{"key":"1190_CR254","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S1470-2045(23)00005-0","volume":"24","author":"R Rahman","year":"2023","unstructured":"Rahman, R. et al. Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. Lancet Oncol. 24, e161\u2013e171 (2023).","journal-title":"Lancet Oncol."},{"key":"1190_CR255","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S1470-2045(21)00488-5","volume":"22","author":"R Rahman","year":"2021","unstructured":"Rahman, R. et al. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 22, e456\u2013e465 (2021).","journal-title":"Lancet Oncol."},{"key":"1190_CR256","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","volume":"23","author":"J Felsberg","year":"2017","unstructured":"Felsberg, J. et al. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. Clin. Cancer Res. 23, 6846\u20136855 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR257","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/ijc.28576","volume":"134","author":"M Weller","year":"2014","unstructured":"Weller, M. et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int. J. Cancer 134, 2437\u20132447 (2014).","journal-title":"Int. J. Cancer"},{"key":"1190_CR258","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jamaoncol.2022.5985","volume":"9","author":"S Agrawal","year":"2023","unstructured":"Agrawal, S. et al. Use of single-arm trials for US Food and Drug Administration drug approval in oncology, 2002-2021. JAMA Oncol. 9, 266\u2013272 (2023).","journal-title":"JAMA Oncol."},{"key":"1190_CR259","first-page":"1200","volume":"2018","author":"PK Mangat","year":"2018","unstructured":"Mangat, P. K. et al. Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis. Oncol. 2018, 1200 (2018).","journal-title":"JCO Precis. Oncol."},{"key":"1190_CR260","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","volume":"574","author":"DL van der Velden","year":"2019","unstructured":"van der Velden, D. L. et al. The drug rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature 574, 127\u2013131 (2019).","journal-title":"Nature"},{"key":"1190_CR261","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/jnci\/djz245","volume":"112","author":"KT Flaherty","year":"2020","unstructured":"Flaherty, K. T. et al. The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design. J. Natl Cancer Inst. 112, 1021\u20131029 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"1190_CR262","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","volume":"19","author":"TW Laetsch","year":"2018","unstructured":"Laetsch, T. W. et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study. Lancet Oncol. 19, 705\u2013714 (2018).","journal-title":"Lancet Oncol."},{"key":"1190_CR263","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41591-025-03928-9","volume":"31","author":"W Wick","year":"2025","unstructured":"Wick, W. et al. Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1\/2a N2M2 umbrella trial. Nat. Med. 31, 3534\u20133541 (2025).","journal-title":"Nat. Med."},{"key":"1190_CR264","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","volume":"24","author":"BM Alexander","year":"2018","unstructured":"Alexander, B. M. et al. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin. Cancer Res. 24, 737\u2013743 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR265","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","volume":"25","author":"NL Albert","year":"2024","unstructured":"Albert, N. L. et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 25, e29\u2013e41 (2024).","journal-title":"Lancet Oncol."},{"key":"1190_CR266","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1093\/neuonc\/noaf103","volume":"27","author":"S Deacon","year":"2025","unstructured":"Deacon, S. et al. ROBIN: a unified nanopore-based assay integrating intraoperative methylome classification and next-day comprehensive profiling for ultra-rapid tumor diagnosis. Neuro-Oncology 27, 2035\u20132046 (2025).","journal-title":"Neuro-Oncology"},{"key":"1190_CR267","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1200\/JCO.2015.61.1525","volume":"33","author":"MM Gounder","year":"2015","unstructured":"Gounder, M. M. et al. Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors. J. Clin. Oncol. 33, 3186\u20133192 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR268","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1200\/JCO.2011.36.6328","volume":"29","author":"PY Wen","year":"2011","unstructured":"Wen, P. Y. et al. It is time to include patients with brain tumors in phase I trials in oncology. J. Clin. Oncol. 29, 3211\u20133213 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR269","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12652-5","volume":"24","author":"W Zhou","year":"2024","unstructured":"Zhou, W. et al. Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022. BMC Cancer 24, 898 (2024).","journal-title":"BMC Cancer"},{"key":"1190_CR270","doi-asserted-by":"publisher","first-page":"D1097","DOI":"10.1093\/nar\/gkad831","volume":"52","author":"L Shen","year":"2024","unstructured":"Shen, L. et al. ADCdb: the database of antibody-drug conjugates. Nucleic Acids Res. 52, D1097\u2013D1109 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1190_CR271","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10048-024-00793-5","volume":"26","author":"V Prakash","year":"2024","unstructured":"Prakash, V. & Gabrani, R. Epigenetic dysregulation in glioblastoma: potential pathways to precision medicine. Neurogenetics 26, 5 (2024).","journal-title":"Neurogenetics"},{"key":"1190_CR272","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.3390\/cells11244063","volume":"11","author":"R Visintin","year":"2022","unstructured":"Visintin, R. & Ray, S. K. Intersections of ubiquitin-proteosome system and autophagy in promoting growth of glioblastoma multiforme: challenges and opportunities. Cells 11, 4063 (2022).","journal-title":"Cells"},{"key":"1190_CR273","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdag144","author":"A Lucas","year":"2026","unstructured":"Lucas, A. et al. Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab. Neurooncol. Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdag144 (2026).","journal-title":"Neurooncol. Adv."},{"key":"1190_CR274","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","volume":"27","author":"L Nayak","year":"2021","unstructured":"Nayak, L. et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clin. Cancer Res. 27, 1048\u20131057 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR275","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA2000","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. Efficacy and safety of STUPP regimen with or without anlotinib for newly diagnosed glioblastoma: results of a multicenter, double-blind, randomized phase II trial. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA2000 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1190_CR276","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad116","author":"TT Batchelor","year":"2023","unstructured":"Batchelor, T. T. et al. NRG\/RTOG 0837: randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. Neurooncol. Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdad116 (2023).","journal-title":"Neurooncol. Adv."},{"key":"1190_CR277","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-19-0133","volume":"25","author":"AC Tien","year":"2019","unstructured":"Tien, A. C. et al. A phase 0 trial of ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic- and pharmacokinetic-guided expansion cohort. Clin. Cancer Res. 25, 5777\u20135786 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1190_CR278","doi-asserted-by":"publisher","unstructured":"Carpentier, A. F. et al. Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: a phase II study. J. Clin. Oncol. 41, https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2005 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.2005"},{"key":"1190_CR279","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/neuonc\/noad137.060","volume":"25","author":"SJ Derby","year":"2023","unstructured":"Derby, S. J. et al. OS09.3.A Final results of the MGMT unmethylated arm of paradigm-2: a phase I study of olaparib and radiotherapy in patients with newly diagnosed glioblastoma (GBM). Neuro-Oncology 25, ii20\u2013ii21, https:\/\/doi.org\/10.1093\/neuonc\/noad137.060 (2023).","journal-title":"Neuro-Oncology"},{"key":"1190_CR280","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.ijrobp.2024.07.217","volume":"120","author":"JT Yang","year":"2024","unstructured":"Yang, J. T. et al. Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 120, S119\u2013S120 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01190-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01190-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01190-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:03:04Z","timestamp":1792411384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01190-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":280,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1190"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01190-7","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"20 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.T. has acted as a consultant or adviser of Bayer, FORE, GSK, Novocure, Resilience, and Servier and has received research funding from Amgen and Sanofi. P.F. has acted as a consultant and speaker for Servier. A.I. owns shares of Immunomica srl. D.C. has received honoraria for lectures and consultancy from Servier, research support from NovoCure, royalties from the sales of the\n                      BRAF\n                      V600E\n                      -mutation-specific antibody VE1 (Ventana, Roche), and is a cofounder and shareholder of Heidelberg Epignostix GmbH. M.G. has acted as a consultant or adviser for or received travel reimbursement from Carthera, Evgen Pharm, MyTomorrows, Nuvation Bio and Servier Medical Affairs. R.R. has acted as a consultant and\/or adviser for Servier Pharmaceuticals, St. Lucia Consulting and Telix Pharmaceuticals. R.V. owns equity in Boundless Bio. M.P. has acted as a consultant and\/or advisor forAbbVie, AdAcAp, Adastra, AstraZeneca, Bayer, BMJ Journals, B\u00f6hringer-Ingelheim, Bristol-Myers Squibb, CMC Contrast, Daiichi Sankyo, Gan & Lee Pharmaceuticals, Gerson Lehrman Group (GLG), GlaxoSmithKline, ITM Oncologics GmbH, Lilly, Medac, Medahead, MedMedia, Medscape, Merck Sharp & Dome, Miltenyi, Mundipharma, Nerviano Medical Sciences, Novartis, OncLive, Roche, Sanofi, Servier, Telix and TocagenJanssen. M.v-d.B. has received honoraria from AstraZeneca, Boehringer, Chimerix, Fore Biotherapeutics, Genenta, Incyte, Nuvation, and Servier and has received research support from Boehringer and travel support from Servier. P.Y.W. has acted as a consultant and\/or advisor for Alexion\/AstraZeneca, Black Diamond, Chimerix, Day One Bio, Fore Biotherapeutics, Genenta, Glaxo Smith Kline, Imvax, Kintara, Merck, Mundipharma, Nerviano, Nuvation Bio, Novartis, Novocure, Nuvation Bio, Medical Sciences, Rigel, Sapience, Servier, and Telix and research support from AstraZeneca, Black Diamond, Bristol Meyers Squibb, Chimerix, Eli Lily, Erasca, Global Coalition For Adaptive Research, MediciNova, Merck, Nerviano, Novartis, Philogen, Quadriga, Servier. E.A. declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}